Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Gelderblom

Showing results (51-60 of 488) with videos related to

Pageof 49
Sort By:
Pharmacogenetics and Genomics|February 15, 2013
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancerLieke H van Huis-Tanja, Hans Gelderblom, Cornelis J A Punt, et al.
Future Oncology (London, England)|September 17, 2024
MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patientsXiaohui Niu, Vinod Ravi, Boyao Shan, et al.
Cancers|August 29, 2024
Machine Learning versus Cox Models for Predicting Overall Survival in Patients with Osteosarcoma: A Retrospective Analysis of the EURAMOS-1 Clinical Trial DataMarta Spreafico, Audinga-Dea Hazewinkel, Michiel A J van de Sande, et al.
Plos One|December 18, 2018
Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximabJara Baas, Lisanne Krens, Stefan Bohringer, et al.
Pharmacogenomics|July 7, 2010
Pharmacogenetics of tomorrow: the 1 + 1 = 3 principleJan Pander, Judith A M Wessels, Ron H J Mathijssen, et al.
The Oncologist|November 6, 2008
False-positive serum human chorionic gonadotropin (HCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literatureBart E P B Ballieux, Nir I Weijl, Hans Gelderblom, et al.
Cancers|April 30, 2021
Treatment Strategies for Metastatic Soft Tissue SarcomasLisette M Wiltink, Rick L M Haas, Hans Gelderblom, et al.
Drug Discovery Today|September 24, 2014
Individualized dosing of tyrosine kinase inhibitors: are we there yet?Djoeke de Wit, Henk-Jan Guchelaar, Jan den Hartigh, et al.
Pharmacogenomics|May 17, 2016
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patientsCarin Atc Lunenburg, Maurice C van Staveren, Hans Gelderblom, et al.
Cancers|April 27, 2024
Bevacizumab Treatment for Patients with <i>NF2</i>-Related Schwannomatosis: A Single Center ExperienceJules P J Douwes, Erik F Hensen, Jeroen C Jansen, et al.
Pageof 49

Showing results (51-60 of 488) with videos related to

Sort By:
Pageof 49
Pharmacogenetics and Genomics|February 15, 2013
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancerLieke H van Huis-Tanja, Hans Gelderblom, Cornelis J A Punt, et al.
Future Oncology (London, England)|September 17, 2024
MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patientsXiaohui Niu, Vinod Ravi, Boyao Shan, et al.
Cancers|August 29, 2024
Machine Learning versus Cox Models for Predicting Overall Survival in Patients with Osteosarcoma: A Retrospective Analysis of the EURAMOS-1 Clinical Trial DataMarta Spreafico, Audinga-Dea Hazewinkel, Michiel A J van de Sande, et al.
Plos One|December 18, 2018
Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximabJara Baas, Lisanne Krens, Stefan Bohringer, et al.
Pharmacogenomics|July 7, 2010
Pharmacogenetics of tomorrow: the 1 + 1 = 3 principleJan Pander, Judith A M Wessels, Ron H J Mathijssen, et al.
The Oncologist|November 6, 2008
False-positive serum human chorionic gonadotropin (HCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literatureBart E P B Ballieux, Nir I Weijl, Hans Gelderblom, et al.
Cancers|April 30, 2021
Treatment Strategies for Metastatic Soft Tissue SarcomasLisette M Wiltink, Rick L M Haas, Hans Gelderblom, et al.
Drug Discovery Today|September 24, 2014
Individualized dosing of tyrosine kinase inhibitors: are we there yet?Djoeke de Wit, Henk-Jan Guchelaar, Jan den Hartigh, et al.
Pharmacogenomics|May 17, 2016
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patientsCarin Atc Lunenburg, Maurice C van Staveren, Hans Gelderblom, et al.
Cancers|April 27, 2024
Bevacizumab Treatment for Patients with <i>NF2</i>-Related Schwannomatosis: A Single Center ExperienceJules P J Douwes, Erik F Hensen, Jeroen C Jansen, et al.
Pageof 49